Umbilical cord blood transplants by Soldevila, A. & Universitat Autònoma de Barcelona. Facultat de Biociències
UMBILICAL CORD BLOOD TRANSPLANTS 
Soldevila A. – Genetics Degree. Facultat de Biociències. Universitat Autònoma de Barcelona – Barcelona (Catalonia – Spain) 
Introduction 
 
In the last 20 years, the experience indicates that umbilical cord blood (UCB), a rich source of hematopoietic stem cells (HSC), is a valid alternative to bone marrow (BM) and peripheral blood stem cells (PBSC) transplants. It has been 
used successfully for patients suffering hematologic, immunologic, genetic and oncologic disorders. 
Several studies have shown that the number of nucleated cells (NC) is the most important factor for engraftment while some degree of HLA mismatch is acceptable.  
This review is focused in explain the main characteristics of UCB and in compare this source with alternatives. The differences between adult and pediatric patients will be contrasted and all the premises for donor selection will be 
cited.  Finally, the ethical issue of having a savior sibling is reported as all the procedure that must be done to have a matching and disease-free sibling. 
 Clearly, CBT has become an important HSC source increasingly used which presents many advantages respect 
BM and PBSC, although each case requires different monitoring and maybe not using this source. 
 
 Nowadays, people try to get a wider range of use of this source like in adult cases. The number of cells is been 
reported as a limiting factor but the solution has been sought and found and a new strategy is being 
implemented consisting of administering two partially patched CB grafts called doubleCBT. 
 
 Donor selection is a complicated procedure because of the high population variability of the HLA system. Every 
single HLA mismatch can change the transplant outcome and can contribute with the graft rejection (GVHD), 
with worse overall survival and with the cited complications. 
 
 One of the most important advantage is that the cells are embryonic stem cells, so they don’t have the 
immunity system developed and this is why they have lower rates of GVHD. 
 
 Regarding the second part of this review, the procedure of PGD for savior siblings is well established and it is 
possible to have a matching and healthy child to save another. However, this issue has ethical background and 
debate with important disagrees, different expert opinions and views that have to be considered. However, PGD 
for HLA-typing has an extra sort, have a healthy child and the chance to save his/her sibling. 
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PROS 
 
-Immediate availability: UCB banks → 
important source of rare HLA haplotypes  
 
- HSCT can be performed with 3-4/6 match → 
99% of all patients can find acceptable UCB 
units. 
 
-Favorable alloreactivity:  
Low grade II-IV of acute and chronic GVHD 
frequencies.  
 
- UCBT is advantageous for children requiring 
urgent transplantation. 
CONS 
 
- The cell dose is a clearly limitation of this 
source. 
 - ↑Risk of graft failure 
 - Contributes to a lower neutrophil and 
 platelet engraftment ratios 
 
- Single one-time availability: transplant 
strategies must be designed around a single 
use of a small cell product. 
 
- Immune reconstitution is delayed because 
of the immaturity of the newborn immune 
system. 
 
Comparison with other sources UCB Pros and Cons 
Peripheral 
Blood 
Bone 
Marrow 
No anesthesia, no need for 
hospitalization or blood transfusion 
Collection of megadoses of stem cells 
vs. 
Faster neutrophil and platelet engraftment 
Drugs to mobilize the hematopoietical 
stem cells from BM to PB 
*No differences for relapse, acute GVHD, 
transplant-relateid mortality or survival rates 
Higher chronic graft-versus-host-disease 
frequency 
Differences between adult and pediatric patients 
Low cell 
dose to overcome 
doubleUCBT 
4/6 to 6/6 
HLA-matched 
↓Relapse risk 
↓Acute and chronic GVHD 
 
Delayed engraftment 
↑Risk early non-relapse mortality 
Presence of  
donor-specific antibodies 
↑Graft failure 
↑Mortality 
↑Time to neutrophil and 
platelet engraftment 
results in 
Necessity to screen for DSAs 
Single unit 
dominance 
Elimination via immunologic reaction 
Dominant unit:  
        ↑% Cells postthaw 
         superior quality 
        ↑Engraftment potential 
Donor selection 
Human Leukocyte Antigen Complex 
- Located in 6p21 
- Large nº of genes → Immune System function  
- Encodes for cell surface Antigenes 
2 classes 
HLA I: A, B and C alleles 
HLA II: DR, DQ and DP alleles 
HLA typing is based on: 
       - exons 2 and 3 polymorphisms        
         for class I  
       - exon 2 polymorphism for class II 
↑Extensive 
polymorphisms 
Diversity arises from exchange of nucleotide 
sequence cartouches between recombinant pairs 
AGCTATTAGCCA CCGATGGACTATG 
HLA typing is a challenging task 
↑ Specificity → ↑Difficult to find a donor 
Increase of donors in BMDW 
↑ Precise probability 
High resolution HLA matching: 
     - improves transplant outcomes 
     - increases patient survival 
8/8 matched donors →  HLA A, 
B, C and DRB1  
One-HLA class I mismatch as a 
2nd choice 
Each additional mismatch → 
survival differences of 9%-10% 
HLA matching 
HLA A, B and C: 
increased risk of 
acute GVHD 
Risks associate with 
single locus mismatches 
HLA A, C and DRB1: 
treatment-related 
mortality and mortality 
Most permissible 
Allelic HLA C and 
DQB1 mismatches 
are the most 
permissible 
HLA C ≠ outcomes if 
Antigenic 
mismatch 
Allellic 
mismatch 
↑ Transplant  
risks 
No ↑  
transplant risks 
Reasons: 
 
   - Poor imunogenicity of common HLA C allelic products 
   - Presence of killer immunoglobulin like receptor (KIR)      
     binding HLA C epitope are more common in antigenic  
     mismatches 
DPB1 
The latest 
addition 
10/10 matched donors 
DPB1 mismatches → Graft failure and GVHD 
                                 → Can induce alloreactive T-cell response 
Mismatches can be 
Permissible if 
Non-Permissible → Both mismatches belong to different groups → They must be avoid. 
Alleles in the patient and donor are from the same T-cell-epitope group 
Both the patient and the donor have at least one allele from group 1 
Neither the patient nor donor had a group 1 allele, but both had at one group 2 allele 
*No GVHD or HVGD 
Savior siblings 
Ovarian stimulation 
Oocyte aspiration 
Fertilization by ICSI 
Embryo culture 
Embryo biopsy 
Genetic diagnosis by 
PCR 
Procedure 
• PCR → biopsy of 1 or 2 cells at the 8-cell stage or from the 
trophectoderm at the blastocyst stage 
 
• The disease of the sibling must allow the procedure waiting period 
 
• The collection of harvested HSC needs at least to be 3.7·107 NC/kg 
 
•        Possibility of detecting recombination events between HLA genes 
Embryo  
selection 
Healthy – Disease-free  
Matched with the ill sibling 
Specific PCR protocol for each family 
Optimized by a protocol based 
on short tandem repeat markers 
No need for a specific design 
for each couple 
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Savior sibling → ethical issue: 
his/her welfare . 
 
√ Gift of life and saving his /her ill 
sibling life 
√ The parents make so much 
effort → the kid will be loved 
√ No important physical risks 
associated with harvesting HSC 
 
X Emotional endangerment 
becausa of the motivation for its 
conception 
X Emotional stress if the 
transplant fails 
Ill sibling  
 
 
√ A savior sibling is the best 
option 
         - ↓  post-transplant    
            complications 
 
X Psychosocial and moral burden 
because they receive a gift that is 
inherently unreciprocal 
X Possibility of deterioration of 
the relationship between siblings 
The mother 
 
√ Chance to save their ill child life 
and to bring a new life  
 
X Physical risks of any pregnancy 
X ↑ Emotional stress 
Potential  fate of unusued 
embryos → embroiled in 
discussion about abortion and 
rights of human life 
 
- Kantian Dictum 
doubleUCBT 
High population 
variability 
